Vytorin Headache Grows With Shareholder Suit

Law360, New York (April 4, 2008, 12:00 AM EDT) -- In the wake of the Vytorin controversy, a proposed class action is accusing Merck & Co. and its leaders of deliberately trying to mislead shareholders over the cholesterol drug in order to pump up the company's stock.

On Thursday, plaintiffs filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Merck and its chairman. The suit says Merck hoodwinked the investing public into believing that Vytorin was an effective treatment against high cholesterol in order to artificially inflate the share price....
To view the full article, register now.